Not Signed In -
Campylobacter Infection |
Campylobacter Infections |
Clinical Trial: A Study to Evaluate Ertapenem Versus It''s Comparator in the Treatment of Complicated Intra-Abdominal Infections in Adults
This study is no longer recruiting patients.
|
Purpose
This was a prospective, randomized, controlled, open, and multi-center trial conducted to compare the clinical efficacy and safety of ertapenem with it''''s comparator before or following adequate surgical management of complicated intra-abdominal infection.
| Condition | Intervention | Phase |
|---|---|---|
| Complicated intra-abdominal infection | Drug: MK0826; ertapenem | Phase IV |
MedlinePlus consumer health information
Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study
Official Title: A Prospective, Multicenter, Open, Randomized, Comparative Study to Evaluate the Safety and Efficacy of Ertapenem Versus It''''s Comparator in the Treatment of Complicated Intra-Abdominal Infections in Adults
Further Study Details:
Study start: January 2004
Eligibility
Ages Eligible for Study: 18 Years - 75 Years, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- Males or females between the ages of 18 and 75 who have complicated intra-abdominal infection.
Location Information
Korea, Republic of
MSD Korea Ltd., Seoul, 121-705, Korea, Republic of
Study chairs or principal investigators
Medical Monitor, Study Director, Merck
More Information
Study ID Numbers: 2005_068
Last Updated: September 10, 2005
Record first received: September 7, 2005
ClinicalTrials.gov Identifier: NCT00157898
Health Authority: Korea: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-09-13
Last Updated: September 10, 2005
Record first received: September 7, 2005
ClinicalTrials.gov Identifier: NCT00157898
Health Authority: Korea: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-09-13
email this page
print this page
bookmark this page
feedback on this page
